combination therapy with glp-1 receptor agonist and sglt2 inhibitor Effect of treatment glucagon-like peptide-1 agonists sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study SGLT-2 inhibitors, GLP-1 receptor agonists,
Description
Additionally, given that the CPRD is a general practice database, prescriptions written by specialists are not captured, which may be another source of exposure misclassification

Key Segment Analysis 15.2

Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction

95% CI, 0.96-3.85, respectively)
[DOI] [PMC free article] [PubMed] [Google Scholar] 16.Pi-Sunyer X, et al

However, the true measure of success in my practice is not just the number on the scale, but the quality of the weight loss and the overall increase in healthspan, states Dr
